Recognition: unknown
Injectable Thermochemical Micro-Explosion for Prompt Thrombolysis via Liquid Alkali Metal
Pith reviewed 2026-05-08 03:33 UTC · model grok-4.3
The pith
Liquid alkali metal in oil clears blood clots in under 90 seconds via micro-explosions, chemical breakdown, and heat.
A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.
Core claim
The authors report that the LAM@oil system enables prompt, efficient and safe vascular recanalization within an ultrafast timeframe of less than 90 seconds through a synergistic triple-action mechanism of mechanical micro-explosions, alkaline ablation from highly localized exothermic chemical reactions, and thermal thrombolysis from elevated temperature. Upon completion, the non-toxic reaction byproducts consisting of sodium and potassium ions exhibit physiologically biocompatible and metabolizable effects. In tests the system shows significantly higher thrombolytic efficacy than urokinase, with residual thrombus area percent of 10.87 percent plus or minus 7.16 percent versus 80.86 percent,
What carries the argument
The LAM@oil system of liquid alkali metal encapsulated in dimethyl silicone oil, which produces localized micro-explosions, alkaline chemical reactions, and heat to disrupt thrombus tissue.
If this is right
- Vascular recanalization occurs within less than 90 seconds after injection.
- Thrombolytic efficacy exceeds that of urokinase, leaving roughly 11 percent residual thrombus versus 81 percent.
- No bleeding risks occur, unlike those associated with standard thrombolytic drugs.
- Reaction byproducts consist only of non-toxic, metabolizable sodium and potassium ions.
- The method offers a byproduct-free and cost-effective option for managing acute thrombosis.
Where Pith is reading between the lines
- Rapid action could shorten emergency response times for clot-related events such as strokes.
- The approach might reduce reliance on invasive catheter procedures in some cases.
- Extension to smaller vessels or different clot compositions would require targeted testing.
- Widespread use could lower overall mortality from thrombotic vascular diseases if safety holds in humans.
Load-bearing premise
The micro-explosions, localized alkaline reactions, and heat generation will remain confined to the thrombus without damaging adjacent healthy vessel walls or producing systemic toxicity when applied in living blood vessels.
What would settle it
In vivo animal experiments showing vessel wall damage, perforation, or systemic side effects after LAM@oil injection into living vessels would disprove the localization and safety claims.
read the original abstract
Thrombotic vascular diseases contribute to significant global mortality, yet current therapeutic strategies face persistent challenges including bleeding risks, suboptimal efficiency, and procedural complexity. Here, we report a micro-explosive thermochemical thrombolysis (METCT) therapy via injectable liquid alkali metal (LAM) encapsulated in dimethyl silicone (LAM@oil), which enables prompt, efficient and safe vascular recanalization within an ultrafast timeframe (< 90 seconds). This LAM@oil system effectively disrupts thrombus tissue through a synergistic triple-action mechanism: Mechanical micro-explosions forces, alkaline ablation due to highly localized exothermic chemical reactions, and thermal thrombolysis mediated by elevated temperature. Upon thrombolysis completion, the non-toxic reaction byproducts (sodium and potassium ions) exhibit physiologically biocompatible and metabolizable effects. Critically, the LAM@oil demonstrates significantly higher thrombolytic efficacy compared to clinically available thrombolytic drugs (residual thrombus area percent 10.87%+-7.16% for LAM@oil vs. 80.86%+-13.32% for urokinase), with no associated bleeding risks. This strategy opens a byproduct-free, cost-effective, and high-efficiency alternative to conventional thrombolytics, holding big potential for clinical translation in acute thrombosis management.
Editorial analysis
A structured set of objections, weighed in public.
Referee Report
Summary. The manuscript reports an injectable LAM@oil system (liquid alkali metal encapsulated in dimethyl silicone) for thrombolysis that achieves vascular recanalization in <90 seconds via a triple-action mechanism of mechanical micro-explosions, localized alkaline ablation from exothermic reactions, and thermal effects. It claims markedly superior efficacy to urokinase (residual thrombus area 10.87%±7.16% vs. 80.86%±13.32%) with no bleeding risks, physiologically biocompatible Na/K byproducts, and potential for clinical translation in acute thrombosis.
Significance. If the in vivo safety and efficacy data hold, the approach would represent a substantial advance over existing thrombolytics by providing ultrafast, byproduct-free recanalization without bleeding complications, addressing key limitations in current acute thrombosis management.
major comments (3)
- [Abstract, Results] Abstract and Results: The headline efficacy comparison (residual thrombus 10.87%±7.16% vs. 80.86%±13.32%) and <90 s timeframe are presented without reported sample sizes, number of replicates, statistical tests, or explicit distinction between in vitro/ex vivo and in vivo models; this directly undermines assessment of whether the data support the superiority claim.
- [Abstract, Discussion] Safety and in vivo validation: The central claim that micro-explosions, alkaline reactions, and heat remain confined to the thrombus without vessel-wall damage, perforation, or embolization rests on the unverified assumption of localization in living vessels; no histological data on endothelial integrity or downstream effects are referenced to secure the 'no associated bleeding risks' and 'physiologically biocompatible' assertions.
- [Methods] Methods: Full experimental details on controls, thrombus models, injection protocols, and long-term toxicity assessments are insufficient or absent, making it impossible to evaluate reproducibility or whether the triple-action mechanism operates as described under physiological blood flow and vessel compliance.
minor comments (2)
- [Abstract] Clarify the exact composition and encapsulation stability of LAM@oil to avoid ambiguity in the 'oil' carrier.
- [Results] Provide quantitative data on temperature profiles and pH changes during the reaction to support the thermal and alkaline components of the mechanism.
Simulated Author's Rebuttal
We thank the referee for the constructive and detailed review of our manuscript. We have addressed each major comment point by point below, providing clarifications where possible and committing to revisions that strengthen the presentation of our data without altering the core findings.
read point-by-point responses
-
Referee: [Abstract, Results] Abstract and Results: The headline efficacy comparison (residual thrombus area 10.87%±7.16% vs. 80.86%±13.32%) and <90 s timeframe are presented without reported sample sizes, number of replicates, statistical tests, or explicit distinction between in vitro/ex vivo and in vivo models; this directly undermines assessment of whether the data support the superiority claim.
Authors: We agree that these methodological details should be explicitly stated in the Abstract and Results for full transparency. The reported percentages derive from multiple independent replicates across ex vivo thrombus models and in vivo rabbit femoral artery thrombosis experiments, with the <90 s recanalization observed specifically in the in vivo setting. We will revise the Abstract and Results to report sample sizes, replicate numbers, the statistical tests applied (including p-values), and clear model distinctions. This revision will allow readers to properly evaluate the superiority claim. revision: yes
-
Referee: [Abstract, Discussion] Safety and in vivo validation: The central claim that micro-explosions, alkaline reactions, and heat remain confined to the thrombus without vessel-wall damage, perforation, or embolization rests on the unverified assumption of localization in living vessels; no histological data on endothelial integrity or downstream effects are referenced to secure the 'no associated bleeding risks' and 'physiologically biocompatible' assertions.
Authors: We acknowledge the value of histological validation for confirming localization and vessel integrity. Our in vivo experiments showed complete recanalization with no bleeding or acute adverse events, and the reaction byproducts (Na+ and K+ ions) are physiologically normal metabolites. However, we agree that explicit histological sections would better support the safety assertions. We will add relevant histological data and analysis in the revised manuscript to demonstrate preserved endothelial integrity and absence of perforation or embolization. revision: partial
-
Referee: [Methods] Methods: Full experimental details on controls, thrombus models, injection protocols, and long-term toxicity assessments are insufficient or absent, making it impossible to evaluate reproducibility or whether the triple-action mechanism operates as described under physiological blood flow and vessel compliance.
Authors: We agree that expanded methodological detail is necessary for reproducibility. We will substantially revise the Methods section to provide complete protocols for thrombus model preparation (in vitro and in vivo), control conditions, injection parameters (including volumes, rates, and delivery systems), and any long-term biocompatibility or toxicity evaluations performed. These additions will clarify how the triple-action mechanism functions under physiological flow and vessel conditions. revision: yes
Circularity Check
No circularity: purely experimental report with no derivations or fitted predictions
full rationale
The manuscript describes an experimental injectable LAM@oil system for thrombolysis, reporting direct in vitro and in vivo measurements of thrombus disruption via micro-explosions, alkaline reactions, and heat. No equations, parameter fits, theoretical derivations, or predictions appear in the provided text or abstract. Efficacy metrics (e.g., residual thrombus area 10.87% vs 80.86%) are empirical outcomes from controlled comparisons, not outputs derived from inputs by construction. No self-citations of uniqueness theorems or ansatzes are invoked to justify core claims. The work is self-contained against external benchmarks as a methods-and-results paper; the flagged safety assumptions concern empirical validation, not circular logic.
Axiom & Free-Parameter Ledger
Reference graph
Works this paper leans on
-
[1]
School of Biomedical Engineering, Tsinghua University, Beijing 100084, China
-
[2]
State Key Laboratory of Cryogenic Science and Technology, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing 100190, China
-
[3]
Institute of Materials Research & Center of Double Helix, Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China
-
[4]
Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China
-
[5]
These authors contributed equally: Xin Liao, Yi Hou * Corresponding Author. Email: jliu@mail.ipc.ac.cn; weirao@mail.ipc.ac.cn; hua_qu@yeah.net Abstract Thrombotic vascular diseases contribute to significant global mortality, yet current therapeutic strategies face persistent challenges including bleeding risks, suboptimal efficiency, and procedural comple...
-
[6]
Introduction Vascular diseases, particularly thrombus formation, remain a persistent global health challenge, characterized by a high morbidity and mortality rates, especially for cerebral infarction, pulmonary embolism and myocardial infarction (Fig. 1A). These life-threatening conditions impose substantial clinical burdens on healthcare systems worldwid...
-
[7]
The LAM (NaK) exists in a liquid state at room temperature with excellent fluidity, allowing it to be dispersed into micro/nanoscale particles via ultrasonication
Results 2.1 Fabrication and thermochemical characterization of LAM@oil To achieve efficient thrombus dissolution within a short timeframe, we engineered and prepared an injectable thrombolytic agent with biocompatibility, green feature and safety. The LAM (NaK) exists in a liquid state at room temperature with excellent fluidity, allowing it to be dispers...
-
[8]
Discussion The micro-explosive thermochemical thrombolysis (METCT) strategy mediated by injectable liquid alkali metal (LAM@oil) represents a transformative and urgently needed advancement in the treatment of acute thrombotic diseases. Unlike conventional pharmacological thrombolytics, which are hampered by systemic bleeding risks, short half -lives, and ...
-
[9]
The proposed LAM@oil represents a green and synergistic thrombolysis strategy that is injectable, straightforward, economical, and practical
Conclusion In summary, we have established an injectable LAM@oil system with the mechanism of micro- explosive and thermochemical thrombolysis (METCT). The proposed LAM@oil represents a green and synergistic thrombolysis strategy that is injectable, straightforward, economical, and practical. The encapsulation of LAM with dimethylsilicone has been shown t...
-
[10]
Experimental Section Materials Liquid sodium-potassium alloy (NaK), Dimethylsilicone (D806807,Macklin Biochemical Co., 20 Ltd., Shanghai, China), PBS solution (Hyclone, USA) , 10% fetal bovine serum (FBS, Hyclone, USA), DMEM culture medium (Hyclone, USA) , 20% ferric chloride (FeCl ₃, Shanghai Aladdin Biochemical Technology Co., L td., China ), Handheld u...
discussion (0)
Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.